Merck & Company, Inc.

Merck & Company, Inc.

Merck & Company, Inc. operates a corporate defined benefit pension plan for its employees, managed internally with oversight from the company's executive leadership. Robert Davis serves as Chairman, President, and CEO, while Caroline Litchfield holds the role of Executive Vice President and CFO, and Dean Y. Li oversees Merck Research Laboratories (per the firm's official communications). The wealth base derives from Merck's pharmaceutical operations, including blockbuster drugs like Keytruda. Strategy: The pension plan allocates across buyout strategies, targeting private equity, real estate, and infrastructure to match long-duration liabilities. Real estate holdings include the Rahway world headquarters campus in New Jersey, the Upper Gwynedd facility in Pennsylvania, and manufacturing sites in West Point and Elkton, Virginia, plus Wilmington, Delaware, and Dunboyne, Ireland. Investment exposure spans North America and Europe through direct and fund-level commitments. Scale: As a corporate pension sponsor, Merck does not publicly disclose plan-specific AUM. The broader company reported $60.1 billion in revenue for 2024 (per the firm's 2024 annual report). The pension fund's assets are housed within Merck's overall corporate treasury, with no separate external GPs named. The Merck Company Foundation handles the firm's philanthropic giving separately from the pension plan. Structural differentiator: The plan is fully internally managed, distinct from outsourced CIO models common among corporate pensions. This structure gives Merck direct control over asset allocation — likely with a focus on buyout and real asset strategies — while the pension's liabilities remain on the corporate balance sheet. No succession or governance changes have been disclosed in the past 24 months.